Literature DB >> 21160772

Pancreatic cancer: A model cancer for the study of the therapeutic effects of anticoagulants.

Anthony Maraveyas1.   

Abstract

Cancer-related thromboembolic disease is a well recognized syndrome since first described by Armand Trousseau in 1865. Preventing the morbidity and mortality related to thromboembolism in these patients is becoming a priority research area with the advent of new anti-coagulants. It is only recently that randomized trials of improved quality are been undertaken to study this question. Many of these trials however are still not accounting for the heterogeneity of "cancer" in terms of anatomical site, histology, stage and treatment. This editorial review highlights why pancreatic cancer may serve as a model malignancy to study this question.

Entities:  

Keywords:  Anticoagulants; Heparin; Pancreatic Cancer; Thromboembolism; Vascular; Vascular thromboembolic disease

Year:  2009        PMID： 21160772      PMCID： PMC2999087          DOI： 10.4251/wjgo.v1.i1.38

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  11 in total

1.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers.

Authors:  Helen K Chew; Theodore Wun; Danielle Harvey; Hong Zhou; Richard H White
Journal:  Arch Intern Med       Date:  2006-02-27

Review 2.  Pancreatic cancer and thromboembolic disease.

Authors:  Alok A Khorana; Robert L Fine
Journal:  Lancet Oncol       Date:  2004-11       Impact factor: 41.316

3.  Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months.

Authors:  Serenella Conti; Francesco Guercini; Alfonso Iorio
Journal:  Pathophysiol Haemost Thromb       Date:  2003 Jul-2004 Aug

Review 4.  Thrombosis in cancer patients.

Authors:  H F Hillen
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

5.  Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer.

Authors:  Joseph Sgouros; Anthony Maraveyas
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

6.  Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients.

Authors:  M Mandalà; M Reni; S Cascinu; S Barni; I Floriani; S Cereda; R Berardi; S Mosconi; V Torri; R Labianca
Journal:  Ann Oncol       Date:  2007-07-28       Impact factor: 32.976

7.  A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer.

Authors:  M Altinbas; H S Coskun; O Er; M Ozkan; B Eser; A Unal; M Cetin; S Soyuer
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

Review 8.  Oral anticoagulation for prolonging survival in patients with cancer.

Authors:  E A Akl; G Kamath; S Y Kim; V Yosuico; M Barba; I Terrenato; F Sperati; H J Schünemann
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

9.  Trousseau's syndrome - what is the evidence? A population-based autopsy study.

Authors:  Mats Ogren; David Bergqvist; Karin Wåhlander; Henry Eriksson; Nils H Sternby
Journal:  Thromb Haemost       Date:  2006-03       Impact factor: 5.249

Review 10.  Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation.

Authors:  E A Akl; F F van Doormaal; M Barba; G Kamath; S Y Kim; S Kuipers; S Middeldorp; V Yosuico; H O Dickinson; H J Schünemann
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
View more
  1 in total

1.  Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study.

Authors:  Anthony Maraveyas; Farzana Haque; Iqtedar Ahmed Muazzam; Waqas Ilyas; George Bozas
Journal:  Thromb J       Date:  2020-05-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.